Evidence map›Paper›PMID 35008445›Full record

ArticleInternational journal of molecular sciences2021

Antibacterial Therapy by Ag

Anna Jagusiak, Tomasz Gosiewski, Dorota Romaniszyn, Małgorzata Lasota, Anna Wiśniewska, Katarzyna Chłopaś, Barbara Ostrowska, Izabela Kościk, Małgorzata Bulanda

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Anna JagusiakChair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, 31-034 Kraków, Poland.ORCID 0000-0002-4440-5160
Tomasz GosiewskiChair of Microbiology, Department of Molecular Medical Microbiology, Faculty of Medicine, Jagiellonian University Medical College, 31-121 Krakow, Poland.ORCID 0000-0003-4725-5943
Dorota RomaniszynChair of Microbiology, Department of Infection Control and Mycology, Faculty of Medicine, Jagiellonian University Medical College, 31-121 Krakow, Poland.
Małgorzata LasotaChair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, 31-034 Kraków, Poland.ORCID 0000-0002-3293-8568
Anna WiśniewskaChair of Pharmacology, Faculty of Medicine, Jagiellonian University Medical College, 31-531 Krakow, Poland.ORCID 0000-0001-7370-9879
Katarzyna ChłopaśPulmonology and Allergology Clinical Department, University Hospital in Krakow, 30-688 Krakow, Poland.
Barbara OstrowskaChair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, 31-034 Kraków, Poland.ORCID 0000-0002-8251-7673
Izabela KościkChair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, 31-034 Kraków, Poland.
Małgorzata BulandaChair of Microbiology, Department of Infection Control and Mycology, Faculty of Medicine, Jagiellonian University Medical College, 31-121 Krakow, Poland.
Jagiellonian University · PLKrakow Cardiovascular Research Institute · PL

Funding

Ministry of Science and Higher Education N41/DBS/000715National Science Center 2016/21/D/NZ1/02763
6 · The paper itself

Abstract

According to the World Health Organization report, the increasing antibiotic resistance of microorganisms is one of the biggest global health problems. The percentage of bacterial strains showing multidrug resistance (MDR) to commonly used antibiotics is growing rapidly. Therefore, the search for alternative solutions to antibiotic therapy has become critical to combat this phenomenon. It is especially important as frequent and recurring infections can cause cancer. One example of this phenomenon is urinary tract infections that can contribute to the development of human urinary bladder carcinoma. This tumor is one of the most common malignant neoplasms in humans. It occurs almost three times more often in men than in women, and in terms of the number of cases, it is the fifth malignant neoplasm after prostate, lung, colon, and stomach cancer. The risk of developing the disease increases with age. Despite the improvement of its treatment methods, the current outcome in the advanced stages of this tumor is not satisfactory. Hence, there is an urgent need to introduce innovative solutions that will prove effective even in the advanced stage of the disease. In our study, a nanosystem based on ionic silver (Ag

Indexed as

AlbuminsAnti-Bacterial AgentsAnti-Inflammatory AgentsAntineoplastic AgentsBacterial InfectionsCell Line, TumorCongo RedEscherichia coliHumansIonsMicrobial Sensitivity TestsSilverStaphylococcus aureusTriazenesUrinary Bladder NeoplasmsAlbuminsAnti-Bacterial AgentsAnti-Inflammatory AgentsAntineoplastic AgentsCongo RedIonsSilvertitan yellowTriazenesapoptosisbovine serum albumincongo redEscherichia colimigrationminimum bactericidal concentrationminimum inhibitory concentrationnecrosissilver ionsStaphylococcus aureusT24 cell linetitan yellowtumor growth

Identifiers

PMID35008445
PMCPMC8744882
OpenAlexW4200013855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.